Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Navone, N. M.
Right arrow Articles by Logothetis, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navone, N. M.
Right arrow Articles by Logothetis, C. J.
Clinical Cancer Research Vol. 6, 1190-1197, March 2000
© 2000 American Association for Cancer Research


Cancer Biology, Immunology, Cytokines

TabBO: A Model Reflecting Common Molecular Features of Androgen-independent Prostate Cancer1

Nora M. Navone2, Maria del C. Rodriguez-Vargas, William F. Benedict, Patricia Troncoso, Timothy J. McDonnell, Jaim-Hua Zhou, Rajyalakshmi Luthra and Christopher J. Logothetis

Departments of Genitourinary Medical Oncology [N. M. N., C. J. L.], Pathology [P. T., R. L.], Molecular Hemathology and Therapeutics [W. F. B., J-H. Z.], Molecular Pathology [T. J. M.], and Urology [M. d. C. R-V.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

We established two human prostate cancer cell lines, MDA PCa 2a and MDA PCa 2b, the TabBO model system, that reflect common features of human androgen-independent prostate cancer that are not present in other model systems: bone origin, prostate-specific antigen production, androgen receptor expression, and androgen sensitivity. We therefore hypothesized that molecular pathways in our model system reflect common alterations responsible for the progression of a subset of human prostate cancer. Progression to androgen independence has been hypothesized to be largely associated with impairment of the regulation of cell growth or apoptosis of prostate cancer cells. Therefore, in this study, we examined molecular markers known or suspected to be important in prostate cancer progression and key regulators of cell growth and apoptosis: p53, p21WAF1/CIP1, Bcl-2, Bax, retinoblastoma (Rb), and p16INK4A/MTS1. We analyzed the expression of these markers in the cell lines, their tumor of origin, and tumors derived from the cell lines by s.c. inoculation into nude mice. DNA sequencing of the entire open reading frames of the p53 and p21 genes revealed no mutations. Additionally, accumulation of the p53 protein was not found by Western blot analysis, nor was overexpression of the Bcl-2 oncoprotein detected. Bax expression was detected in MDA PCa 2a cells, whereas it was absent in MDA PCa 2b. Rb and p16 protein expression was normal as measured by both Western blot and immunochemical analyses. Immunohistochemical studies of p53, p21, Bcl-2, and Rb in both samples from the original human cancer from which the lines were derived and mouse xenografts derived from the lines revealed similar levels of protein. These results are consistent with reports indicating that 40–50% of bone metastases of prostate cancer have wild-type p53, 50–70% do not overexpress the Bcl-2 protein, and mutations in the p21 gene are rare. Therefore, we conclude that MDA PCa 2a and MDA PCa 2b reflect molecular pathways in a common subset of human androgen-independent prostate cancer and that important molecular players in apoptosis (namely, p53 and Bcl-2) seem to be intact in this subset of androgen-independent prostate cancer. Understanding the signal-transduction pathways operating in these cell lines may help to identify therapeutic targets for prostate cancer.




This article has been cited by other articles:


Home page
Cancer Res.Home page
X.-H. Liu, A. Kirschenbaum, S. Yao, G. Liu, S. A. Aaronson, and A. C. Levine
Androgen-Induced Wnt Signaling in Preosteoblasts Promotes the Growth of MDA-PCa-2b Human Prostate Cancer Cells
Cancer Res., June 15, 2007; 67(12): 5747 - 5753.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Jung, R.-S. Kim, H.-J. Zhang, S.-J. Lee, and M.-H. Jeng
HOXB13 Induces Growth Suppression of Prostate Cancer Cells as a Repressor of Hormone-Activated Androgen Receptor Signaling
Cancer Res., December 15, 2004; 64(24): 9185 - 9192.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, et al.
Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts
Clin. Cancer Res., July 1, 2003; 9(7): 2587 - 2597.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. A. Martinez, J. Yang, E. S. Vazquez, M. del Carmen Rodriguez-Vargas, M. Olive, J.-T. Hsieh, C. J. Logothetis, and N. M. Navone
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells
Carcinogenesis, August 1, 2002; 23(8): 1289 - 1296.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al.
The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Szepeshazi, A. V. Schally, G. Halmos, P. Armatis, F. Hebert, B. Sun, A. Feil, H. Kiaris, and A. Nagy
Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Somatostatin Receptor-positive Experimental Colon Cancers Independently of Their p53 Status
Cancer Res., February 1, 2002; 62(3): 781 - 788.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Yang, K. Fizazi, S. Peleg, C. R. Sikes, A. K. Raymond, N. Jamal, M. Hu, M. Olive, L. A. Martinez, C. G. Wood, et al.
Prostate Cancer Cells Induce Osteoblast Differentiation through a Cbfa1-dependent Pathway
Cancer Res., July 1, 2001; 61(14): 5652 - 5659.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-Y. Hsu, D. Feldman, J. E. McNeal, and D. M. Peehl
Reduced 1{{alpha}}-hydroxylase Activity in Human Prostate Cancer Cells Correlates with Decreased Susceptibility to 25-Hydroxyvitamin D3-induced Growth Inhibition
Cancer Res., April 1, 2001; 61(7): 2852 - 2856.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.